Literature DB >> 22791886

Commercial immunoassays in biomarkers studies: researchers beware!

Nader Rifai, Ian D Watson, W Greg Miller.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22791886     DOI： 10.1373/clinchem.2012.192351

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  7 in total

Review 1.  Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Authors:  Steven L Wood; Margaret A Knowles; Douglas Thompson; Peter J Selby; Rosamonde E Banks
Journal:  Nat Rev Urol       Date:  2013-02-26       Impact factor: 14.432

2.  Evaluation of a research use only luminex based assay for measurement of procalcitonin in serum samples.

Authors:  Charles Garrigan; Jennifer Han; Pam Tolomeo; Katherine J Johnson; Stephen R Master; Ebbing Lautenbach; Irving Nachamkin
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 3.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

4.  Identification and quantification of plasma free salusin-β, an endogenous parasympathomimetic peptide.

Authors:  Kazumi Fujimoto; Akinori Hayashi; Yoshio Kodera; Tatsuya Saito; Takuya Toki; Akifumi Ogawa; Yuji Kamata; Koji Takano; Hideki Katakami; Masayoshi Shichiri
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

5.  Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles.

Authors:  Peggy Sekula; Susan Mallett; Douglas G Altman; Willi Sauerbrei
Journal:  PLoS One       Date:  2017-06-14       Impact factor: 3.240

6.  Mass spectrometry-based proteomic techniques to identify cerebrospinal fluid biomarkers for diagnosing suspected central nervous system infections. A systematic review.

Authors:  Tehmina Bharucha; Bevin Gangadharan; Abhinav Kumar; Xavier de Lamballerie; Paul N Newton; Markus Winterberg; Audrey Dubot-Pérès; Nicole Zitzmann
Journal:  J Infect       Date:  2019-08-09       Impact factor: 6.072

Review 7.  Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.

Authors:  Stephen P Arnerić; Richard Batrla-Utermann; Laurel Beckett; Tobias Bittner; Kaj Blennow; Leslie Carter; Robert Dean; Sebastiaan Engelborghs; Just Genius; Mark Forrest Gordon; Janice Hitchcock; June Kaplow; Johan Luthman; Richard Meibach; David Raunig; Klaus Romero; Mahesh N Samtani; Mary Savage; Leslie Shaw; Diane Stephenson; Robert M Umek; Hugo Vanderstichele; Brian Willis; Susan Yule
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.